ClinicalTrials.gg
Active, not recruitingNCT06315751ALLEVIA2Updated Mar 9, 2026

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

A Phase 2 interventional study of Gemlapodect and Placebo in Tourette Syndrome, sponsored by Noema Pharma AG. Active, not recruiting at 46 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Noema Pharma AG · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
9th of 105
164 · median 33
Started
2024
with 6 others
Phase 2
26 of 139
4 open now
Primary completion
2026-06
later than 6 of 23 live
Registered
130th of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 9th largest by enrollment of the 105 interventional ones that give a count, is one of 7 that started in 2024, is one of 26 in phase 2, reaches primary completion later than 6 of the 23 other live ones, and was the 130th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.

Read the detailed description

Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with Tourette Syndrome (TS). This is a multi-center, double-blind, parallel-arm, placebo-controlled study in patients with TS. Following screening to confirm eligibility and to wash-out previous TS medication during a 14-day placebo run-in, patients will be randomized 1:1 on Day 1 to receive gemlapodect or placebo once daily for 12 weeks. See https://allevia2study.com

03

Conditions studied

  • Tourette Syndrome

Browse trials for

Keywords

  • NOE-105
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Initially, patients aged 18 years onwards, at the time of signing the ICF form. Adolescents aged 12 years and older at the time of signing the ICF/informed assent form will be eligible for inclusion after completion of a sentinel cohort of adults.
  2. Moderate to severe Tourette Syndrome as defined by diagnostic criteria and TS-CGI-S ≥ 4.
  3. Treatment naive or previously treated patients in need of treatment alternative as per investigators judgement.
  4. Patients must discontinue all medications used to treat TS for at least 14 days prior to randomization. Other psychotropic drugs, including stimulants, will be allowed provided they have been stable for at least 30 days prior to randomization and are expected to remain stable for the duration of the study.
  5. within the range 18 to 35 kg/m2 (inclusive).
  6. Women of should only be included after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test. use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  7. Capable of giving signed or consent from their legal representative.
  8. Fluency in the language of the investigator, study staff, and the ICF/informed assent form when applicable.

Exclusion criteria

Exclusion Criteria:

  1. Any medical condition which, in the opinion of the investigator, could interfere with study procedures including but not limited to functional tic-like disorder, secondary tic symptoms accompanied by late-onset tics, Huntington's chorea, malignant TS, neuroacanthocytosis, autism, and history of known intellectual disability that would affect patient's ability to comply with study procedures.
  2. Current active diagnosis of severe anxiety, bipolar disorder, schizophrenia, major depressive disorder (MDD,), or Parkinson's disease. Patients with a history of MDD on selective serotonin reuptake inhibitors treatment stable for at least a month may participate in the study.
  3. A history of severe traumatic brain injury or stroke.
  4. Any unstable medical conditions, severe symptoms, or abnormalities on screening test/examinations, including uncontrolled seizure disorders, which, in the investigator's judgment, will put them at a risk of major AE during this trial, or will interfere with safety and efficacy assessments.
  5. Are undergoing active CBT (including but not limited to comprehensive behavioral intervention for tics, exposure and response prevention, relaxation training) during the last 28 days before the planned date of randomization and until the end of the trial. Patients willing to discontinue their CBT over this period are eligible to enroll in the study.
  6. Known diagnosis of substance abuse or dependence.
  7. Active suicidal ideation or behavior.
  8. Use of prescribed or recreational cannabinoids during the study are prohibited. Prescribed cannabinoids include Epidiolex® (cannabidiol), Marinol® /Syndros® (dronabinol), and Cesamet® (nabilone). These medications will be discontinued during the Screening period. Study participants prescribed cannabinoids for seizure disorders are not eligible for study participation. Recreational cannabinoids, regardless of their form of intake, which include tetrahydrocannabinol and/or cannabidiol, are prohibited.
  9. Strong inhibitors and inducers of are prohibited during the study.
  10. Neurostimulation/deep brain stimulation for TS.
  11. Participation in another clinical study with a study intervention administered in the last 30 days.
  12. Patients with a known to gemlapodect or any of the of the product
  13. Positive urine drug screen for cannabis, cocaine, or nonprescribed opiates.
  14. The person is an employee or family member of an employee of the Sponsor, Investigator, or study site personnel.
  15. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  16. Previous randomization in the present study.
  17. The person is currently committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Gemlapodect

    Escalating doses of NOE-105 capsules

    Drug: Gemlapodect

  • Placebo comparator
    Placebo

    Escalating doses of matching placebo

    Drug: Placebo

Interventions

  • DrugGemlapodect

    Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.

    Also known as: NOE-105

  • DrugPlacebo

    Administered in the form of oral capsules with inert ingredients.

06

What researchers measure

Primary outcomes

  1. Change in tic severity score on the Revised Yale Global Tic Scoring Scale (YGTSS-R)

    YGTSS-R is a clinician rated score that evaluates number, frequency, intensity, complexity and interference of motor and phonic tics with a total score ranging from 0 to 50, with 50 being the most severe and 0 being no tics. Change in YGTSS-R total tic scores from baseline (randomization) to D85 for gemlapodect as compared to placebo. The primary estimand is the difference in means between gemlapodect and placebo for the change in the TTS of the YGTSS-R from baseline (randomization) to D85, in the target patient population of adult and adolescent patients with TS, regardless of whether or not dose reduction, suspension, or treatment discontinuation occurred due to events attributable to treatment, and regardless of change in background medication (dose and product) while under treatment, but in the absence of any new treatment started after discontinuation of investigational intervention

    Time frame: 85 days

Secondary outcomes

  1. Impact on patient functioning

    Change in Sheehan Disability Scale from baseline (randomization) to D85 for gemlapodect as compared to placebo

    Time frame: 85 days

  2. Change in PUTS

    Change in premonitory urge for tics scale from baseline (randomization) to D85 for gemlapodect as compared to placebo

    Time frame: 85 days

  3. Safety and Tolerability of gemlapodect

    The Incidence and severity of adverse events, including serious adverse events and adverse events of special interest

    Time frame: 85 days

  4. Assessment of suicidality and suicidal ideation

    Change in Columbia Suicide Severity Rating Scale (C-SSRS) subscale from baseline(randomization) to D85 for gemlapodect as compared to placebo. The C-SSRS supports suicide risk assessment through a series of simple, plain-language questions to assesses suicidal ideation and suicidal behavior.

    Time frame: 85 days

07

Study locations

46 sites
  • Noema TTS-201 Site #81
    Sun City, Arizona 85351, United States
  • Noema TTS-201 Site #95
    Bellflower, California 90706, United States
  • Noema TTS-201 Site #75
    Glendale, California 91203, United States
  • Noema TTS-201 Site #59
    San Rafael, California 94903, United States
  • Noema TTS-201 Site #21
    Walnut Creek, California 94596, United States
  • Noema TTS-201 Site #54
    Gulf Breeze, Florida 32561, United States
  • Noema TTS-201 Site #05
    Hialeah, Florida 33013, United States
  • Noema TTS-201 Site #97
    Jensen Beach, Florida 34957, United States
  • Noema TTS-201 Site #71
    Largo, Florida 33777, United States
  • Noema TTS-201 Site #44
    Maitland, Florida 32751, United States
  • Noema TTS-201 Site # 74
    Miami, Florida 33136, United States
  • Noema TTS-201 Site #56
    Miami Lakes, Florida 33016, United States
  • Noema TTS-201 Site #61
    Orlando, Florida 32802, United States
  • Noema TTS-201 Site #79
    Atlanta, Georgia 30318, United States
  • Noema TTS-201 Site #87
    Peachtree Corners, Georgia 30071, United States
  • Noema TTS-201 Site #55
    Boston, Massachusetts 02114, United States
  • Noema TTS-201 Site #51
    Ann Arbor, Michigan 48105, United States
  • Noema TTS-201 Site #96
    Saint Charles, Missouri 63304, United States
  • Noema TTS-201 Site #93
    Lincoln, Nebraska 68526, United States
  • NOema TTS-201 Site #19
    New York, New York 10003, United States
  • Noema TTS-201 Site #03
    Stony Brook, New York 11794, United States
  • Noema TTS-201 Site #57
    Charlotte, North Carolina 28211, United States
  • Noema TTS-201 Site #58
    Middleburg Heights, Ohio 44130, United States
  • Noema TTS-201 Site #73
    North Charleston, South Carolina 29405, United States
  • Noema TTS-201 Site #98
    Nashville, Tennessee 37203, United States
  • Noema TTS-201 Site #42
    Dallas, Texas 75243, United States
  • Noema TTS-201 Site #22
    Fort Worth, Texas 76104, United States
  • Noema TTS-201 Site #94
    San Antonio, Texas 78249, United States
  • Noema TTS-201 Site #45
    Orem, Utah 84097, United States
  • Noema TTS-201 Site #18
    Petersburg, Virginia 23805, United States
  • Noema TTS-201 Site #50
    Bellevue, Washington 98007, United States
  • Noema TTS-201 Site #06
    Ghent, 9000, Belgium
  • Noema TTS-201 #07
    Bron, 69677, France
  • Noema TTS-201 Site #08
    Poitiers, 86000, France
  • Noema TTS-201 Site #35
    Düsseldorf, 40225, Germany
  • Noema TTS-201 Site #09
    Hanover, 30625, Germany
  • NOE-TTS-201 Site #25
    Munich, 80336, Germany
  • Noema TTS-201 Site #30
    Budapest, 1013, Hungary
  • Noema TTS-201 Site #13
    Katowice, 40097, Poland
  • Noema TTS-201 Site #14
    Katowice, 40123, Poland
  • Noema TTS-201 Site #26
    Barcelona, 08041, Spain
  • Noema TTS-201 Site #15
    Burgos, 09006, Spain
  • Noema TTS-201 Site #27
    Madrid, 28922, Spain
  • Noema TTS-201 Site #17
    Oviedo, 33011, Spain
  • Noema TTS-201 Site #16
    Sant Cugat del Vallès, 08190, Spain
  • NOE-TTS-201 Site #28
    Seville, 41013, Spain
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2026, 21 months after the start.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Mar 18, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06315751
Lead sponsor
Noema Pharma AG
Responsible party
Sponsor
First posted
Mar 18, 2024
Start date
Sep 10, 2024
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Mar 9, 2026

Study contacts

Clinical Director, MD
study director · Noema Pharma AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion